Sat, Feb 28, 2015, 10:42 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • mr_ssssamsa mr_ssssamsa Dec 31, 2012 6:47 PM Flag

    Analyst comments

    There was an article on Marketwatch today by Mark Hulbert of Hulbert Financial Digest entitled "Small is beautiful, tiny is even better" which argues that the "January effect" works mostly in favor of small-cap companies. He then lists OGXI among 9 companies that he says have a market cap of less than $100 million and are recommended by at least two monitored advisors. Of course, OGXI's market cap, while pitiful enough, is more than $100 million so that makes you wonder about Hulbert right there, but hopefully his point is well taken.

    Other factors could be that the negative pressures of year-end tax selling and the fiscal cliff are abating.

    Next year obviously is make or break for 011 as SYNERGY is expected to report around year-end. I listened to most of Teva's "strategic presentation" a few weeks ago and they downplayed oncology and said hardly anything about 011. On the other hand, they announced they were discontinuing several partnerships for products that are also in clinical trials so the fact that they're not discontinuing the 011 partnership is a good sign I suppose. Or at least a sign that they probably don't have any negative interim results at this time.

    Hopefully 427 will continue to move along nicely in 2013. They've started the trial with Zytiga and according to one of the slide presentations on the OGXI website they hope to report interim data in early 2014. And we may get updates in 2013 on enrollment in the 427 randomized P2 bladder trial that's scheduled to report data in 2014.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 427 CRPC P2 data due out in late Q1/13

      I thought the Synergy trial was powerd (Deaths) to read out Late 2013 and so their would be no comments on any interim results???

      • 1 Reply to boxcarlong
      • OGXI has said there will be an interim analysis but there will be so few events when it occurs that it's very unlikely the trial will be stopped, for either efficacy or futility. They've said the interim wasn't designed for that. Summer in a recent post said that an interim is often done soon after enrollment is complete, which occurred a couple of months ago, though she also said it could take a few months to gather and analyze the data.

        Most likely we'll hear nothing about it but there is an outside chance of news one way or the other.

2.30+0.01(+0.22%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.